# NCT06103864 (NCT06103864)

> A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06103864
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer
- Interventions: Dato-DXd; Durvalumab; Paclitaxel; Nab-paclitaxel; Gemcitabine; Carboplatin; Pembrolizumab
- Enrollment: 625
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 18
- Podcasts: 11
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06103864

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06103864", "email": "<work email>"}; the inbox owner confirms by the emailed link.